The one-year-long study was aimed at evaluating the efficacy of LDH’s digital therapeutics platform, Lyfe, on cardiovascular events, rehospitalisation, medication adherence, vital sign monitoring, and lifestyle changes among heart patients. During the 90-day interim analysis, LDH revealed patients enrolled in the program demonstrated significant improvement, with 90 per cent adhering to the recommended medication, diet, and exercise regimen.
Chennai: Showing the efficacy of digital therapeutics (DTx) among patients with acute coronary syndrome (ACS) and postpercutaneous coronary interventions, Lupin Digital Health (LDH), a DTx platform, has released the results of a study in India.
